ECMO ABI Detection With Hyperfine

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-17
SponsorChildren's Mercy Hospital Kansas City

About this trial

The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.

Eligibility criteria

Qualifiers

Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit

Ages 0-17 years

Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO

Undergoing cardiac surgery

Disqualifiers

Pregnancy

Any patient who has a contraindication to having an MRI

First be reviewed on MRISafety.com to determine MR conditionality

If device is listed as Conditional or Unsafe for a 1.5T or a 3T, device will then be reviewed by MRI Safety Officer or MRI Physician Section chief to determine true conditionality for the portable MRI

Trial design

Treatments tested in this trial

  • Hyperfine

Treatment groups

40 Participants
are divided into 1 treatment group